Menu Menu


AZN Financials       Clear


AZN        0000901832    
Filing Date Form Type Description Document
2020-07-24 6-K BREZTRI AEROSPHERE APPROVED IN THE US FOR THE MAINTENANCE TREATMENT OF COPD View Document
2020-07-22 6-K HOLDING(S) IN COMPANY View Document
2020-07-22 6-K HOLDING(S) IN COMPANY View Document
2020-07-21 6-K HOLDING(S) IN COMPANY View Document
2020-07-21 6-K HOLDING(S) IN COMPANY View Document
2020-07-20 6-K COVID-19 VACCINE AZD1222 SHOWED ROBUST IMMUNE RESPONSES IN ALL PARTICIPANTS IN P View Document
2020-07-16 6-K DIRECTOR DECLARATION View Document
2020-07-09 6-K BRILINTA GRANTED US FDA PRIORITY REVIEW FOR STROKE View Document
2020-07-08 6-K LYNPARZA APPROVED IN THE EU FOR BRCA- MUTATED METASTATIC PANCREATIC CANCER View Document
2020-07-01 6-K TOTAL VOTING RIGHTS View Document
2020-06-30 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2020-06-30 6-K SELUMETINIB GRANTED ORPHAN DRUG DESIGNATION IN JAPAN FOR NEUROFIBROMATOSIS TYPE View Document
2020-06-26 11-K View Document
2020-06-17 6-K HOLDING(S) IN COMPANY View Document
2020-06-17 6-K HOLDING(S) IN COMPANY View Document
2020-06-15 6-K ASTRAZENECA TO SUPPLY EUROPE WITH UP TO 400 MILLION DOSES OF OXFORD UNIVERSITY'S View Document
2020-06-11 6-K EMTN PROGRAMME ROUTINE TECHNICAL UPDATE: PUBLICATION OF PROSPECTUS View Document
2020-06-01 6-K TOTAL VOTING RIGHTS View Document
2020-06-01 6-K BLOCK LISTING INTERIM REVIEW View Document
2020-06-01 6-K LYNPARZA RECOMMENDED FOR APPROVAL IN EU BY CHMP FOR BRCA-MUTATED METASTATIC PANC View Document
2020-06-01 6-K BRILINTA APPROVED IN THE US TO REDUCE THE RISK OF A FIRST HEART ATTACK OR STROKE View Document
2020-05-29 6-K ENHERTUSIGNIFICANTLY IMPROVED TUMOUR RESPONSE RATE AND OVERALL SURVIVAL IN HER2- View Document
2020-05-29 6-K IMFINZI SHOWED A SUSTAINED OVERALL SURVIVAL BENEFIT IN 1ST-LINE EXTENSIVE-STAGE View Document
2020-05-29 6-K TAGRISSO DEMONSTRATED UNPRECEDENTED DISEASE-FREE SURVIVAL IN THE ADJUVANT TREATM View Document
2020-05-26 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2020-05-22 6-K ENHERTU GRANTED ORPHAN DRUG DESIGNATION IN THE US FOR GASTRIC CANCER View Document
2020-05-21 6-K ASTRAZENECA ADVANCES RESPONSE TO GLOBAL COVID-19 CHALLENGE AS IT RECEIVES FIRST View Document
2020-05-20 6-K LYNPARZA APPROVED IN THE US FOR HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT View Document
2020-05-18 6-K ENHERTU US BREAKTHROUGH STATUS FOR LUNG CANCER View Document
2020-05-18 6-K BEVESPI AEROSPHERE APPROVED IN CHINA FOR COPD View Document
2020-05-11 6-K ENHERTU GRANTED BREAKTHROUGH THERAPY DESIGNATION IN THE US FOR HER2-POSITIVE MET View Document
2020-05-11 6-K ASTRAZENECA RECOVERY OF GLOBAL RIGHTS TO BRAZIKUMAB (MEDI2070) FROM ALLERGAN COM View Document
2020-05-11 6-K LYNPARZA APPROVED IN THE US AS 1ST-LINE MAINTENANCE TREATMENT WITH BEVACIZUMAB F View Document
2020-05-06 6-K FARXIGA APPROVED IN THE US FOR THE TREATMENT OF HEART FAILURE IN PATIENTS WITH H View Document
2020-05-01 6-K TOTAL VOTING RIGHTS View Document
2020-04-29 6-K RESULT OF AGM View Document
2020-04-29 6-K AZN: FIRST-QUARTER 2020 RESULTS View Document
2020-04-24 6-K LYNPARZA DEMONSTRATED OVERALL SURVIVAL BENEFIT IN PHASE III PROFOUND TRIAL FOR B View Document
2020-04-17 6-K CHANGES TO ARRANGEMENTS FOR ANNUAL GENERAL MEETING View Document
2020-04-14 6-K KOSELUGO (SELUMETINIB) APPROVED IN US FOR PAEDIATRIC PATIENTS WITH NEUROFIBROMAT View Document
2020-04-14 6-K TAGRISSO PHASE III ADAURA TRIAL WILL BE UNBLINDED EARLY AFTER OVERWHELMING EFFIC View Document
2020-04-02 6-K ASTRAZENECA DIVESTMENT OF MOVANTIK TO REDHILL BIOPHARMA COMPLETED View Document
2020-04-01 6-K TOTAL VOTING RIGHTS View Document
2020-03-31 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2020-03-30 6-K FARXIGA PHASE III DAPA-CKD TRIAL WILL BE STOPPED EARLY AFTER OVERWHELMING EFFICA View Document
2020-03-30 6-K IMFINZI APPROVED IN THE US FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER View Document
2020-03-26 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2020-03-26 6-K LOKELMA APPROVED IN JAPAN FOR THE TREATMENT OF HYPERKALAEMIA View Document
2020-03-20 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2020-03-19 6-K LYNPARZA GRANTED ORPHAN DRUG DESIGNATION IN JAPAN FOR BRCA-MUTATED METASTATIC PA View Document
2020-03-17 6-K IMFINZI CONFIRMED A SUSTAINED OVERALL SURVIVAL BENEFIT IN FINAL ANALYSIS OF THE View Document
2020-03-12 6-K 6-K View Document
2020-03-12 6-K NOTICE OF AGM View Document
2020-03-12 6-K UPDATE ON PHASE III GY004 TRIAL FOR CEDIRANIB ADDED TO LYNPARZA IN PLATINUM-SENS View Document
2020-03-10 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2020-03-06 6-K UPDATE ON PHASE III DANUBE TRIAL FOR IMFINZI AND TREMELIMUMAB IN UNRESECTABLE, S View Document
2020-03-04 6-K FILING OF FORM 20-F WITH SEC View Document
2020-03-03 IRANNOTICE IRANNOTICE View Document
2020-03-03 20-F 20-F View Document
2020-03-03 6-K ANNUAL FINANCIAL REPORT View Document
2020-03-02 6-K TOTAL VOTING RIGHTS View Document
2020-03-02 6-K ASTRAZENECA COMPLETES DIVESTMENT AGREEMENT WITH ATNAHS PHARMA FOR ESTABLISHED HY View Document
2020-02-27 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2020-02-25 6-K ASTRAZENECA DIVESTS GLOBAL RIGHTS TO MOVANTIK View Document
2020-02-19 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2020-02-14 6-K AZN: FULL-YEAR AND Q4 2019 RESULTS View Document
2020-02-07 4 4 View Document
2020-02-07 3 3 View Document
2020-02-07 SC 13D SC 13D View Document
2020-02-06 EFFECT View Document
2020-02-05 SC 13G/A View Document
2020-02-03 6-K TOTAL VOTING RIGHTS View Document
2020-01-30 SC 13G SC 13G View Document
2020-01-27 SC 13G/A SEC SCHEDULE 13G View Document
2020-01-27 6-K PHASE II DESTINY-GASTRIC01 TRIAL OF ENHERTU VERSUS CHEMOTHERAPY MET PRIMARY ENDP View Document
2020-01-27 6-K ASTRAZENECA TO RECOVER THE GLOBAL RIGHTS TO BRAZIKUMAB (MEDI2070) FROM ALLERGAN View Document
2020-01-27 6-K BRILINTA MET PRIMARY ENDPOINT IN PHASE III THALES TRIAL IN STROKE View Document
2020-01-27 6-K ASTRAZENECA DIVESTS RIGHTS TO ESTABLISHED HYPERTENSION MEDICINES View Document
2020-01-22 F-6 FORM F-6 View Document
2020-01-21 6-K LYNPARZA REGULATORY SUBMISSION GRANTED PRIORITY REVIEW IN THE US FOR HRR-MUTATED View Document
2020-01-21 6-K IMFINZI AND TREMELIMUMAB GRANTED ORPHAN DRUG DESIGNATION IN THE US FOR LIVER CAN View Document
2020-01-13 6-K LYNPARZA REGULATORY SUBMISSION GRANTED PRIORITY REVIEW IN THE US FOR 1ST-LINE MA View Document
2020-01-13 6-K UPDATE ON PHASE III STRENGTH TRIAL FOR EPANOVA IN MIXED DYSLIPIDAEMIA View Document
2020-01-06 6-K LOKELMA APPROVED IN CHINA FOR THE TREATMENT OF ADULT PATIENTS WITH HYPERKALAEMIA View Document
2020-01-06 6-K FARXIGA GRANTED FDA PRIORITY REVIEW FOR PATIENTS WITH HEART FAILURE WITH REDUCED View Document
2020-01-02 6-K TOTAL VOTING RIGHTS View Document
2019-12-30 6-K LYNPARZAAPPROVED IN THE US AS A 1ST-LINE MAINTENANCE TREATMENT OF GERMLINE BRCA- View Document
2019-12-23 6-K ASTRAZENECA'S TRIPLE-COMBINATION THERAPY APPROVED IN CHINA FOR PATIENTS WITH COP View Document
2019-12-23 6-K ENHERTU (TRASTUZUMAB DERUXTECAN) APPROVED IN THE US FOR HER2-POSITIVE UNRESECTAB View Document
2019-12-20 6-K ASTRAZENECA DIVESTS RIGHTS TO ARIMIDEX AND CASODEX IN EUROPE AND CERTAIN ADDITIO View Document
2019-12-17 6-K FDA PANEL BACKS LYNPARZA USE FOR PANCREATIC CANCER View Document
2019-12-16 6-K SEROQUEL RIGHTS AGREEMENT COMPLETE: EUROPE, RUSSIA View Document
2019-12-12 6-K IMFINZI APPROVED IN CHINA FOR THE TREATMENT OF UNRESECTABLE, STAGE III NON-SMALL View Document
2019-12-11 6-K TRASTUZUMAB DERUXTECAN ACHIEVED A TUMOUR RESPONSE RATE OF 60.9% IN PIVOTAL PHASE View Document
2019-12-05 6-K LYNPARZA APPROVED IN CHINA AS A 1ST-LINE MAINTENANCE THERAPY IN BRCA-MUTATED ADV View Document
2019-12-03 6-K ASTRAZENECA DIVESTS RIGHTS TO SEROQUEL AND SEROQUEL XR IN THE US AND CANADA View Document
2019-12-02 6-K BLOCK LISTING INTERIM REVIEW View Document
2019-12-02 6-K TOTAL VOTING RIGHTS View Document
2019-11-29 6-K IMFINZI GRANTED FDA PRIORITY REVIEW FOR THE TREATMENT OF PATIENTS WITH EXTENSIVE View Document
2019-11-21 6-K CALQUENCE APPROVED IN THE US FOR ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEM View Document

Find registration statements, periodic reports, and other forms by typing ticker symbol of a company.

Ticker:

Search company filings and access detailed reports including 10-K, 10-Q, 8-K, and other critical filings. Stay informed on corporate disclosures, regulatory filings, and updates with our easy-to-use EDGAR API filings search tool.



We can also help with your taxes.

Formal Tax

www.formal.tax





(402) 804-8293


Formal Financial App
Google Play - Apple Store

created using: Admin Canvas